E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if the administration of baricitinib to patients with CANDLE, CANDLE-related conditions, juvenile dermatomyositis (JDM), or SAVI, or AGS results in a reduction in the patient’s mean daily diary scores. |
|
E.2.2 | Secondary objectives of the trial |
To determine if the administration of baricitinib to patients with CANDLE, CANDLE-related conditions, juvenile dermatomyositis (JDM), or SAVI, or AGS results in a reduction in the patient’s requirement for oral steroids (patients who are receiving steroids). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Are ≥17.5 months of age (>6 months with AGS). Participants younger than 17.5 months of age (<6 months with AGS) can be considered for enrollment after discussion with the sponsor
• Have systemic signs and symptoms of inflammation as manifested by the presence of two or more of the following symptoms: rash, fever, musculoskeletal pain, headache, fatigue, weakness, respiratory/breathing symptoms, or ulcers/ischemic lesions
• Have an average daily Diary Score of ≥0.5 (CANDLE or AGS Diary; used also for CANDLE-related conditions) or ≥1.0 (SAVI or JDM Diary) assessed over at least 2 weeks prior to entry, if available. Otherwise, participants can complete the diary after study consent is signed during the screening period and meet the inclusion criteria for enrollment into the study
• Are ≥8.5 kilogram (kg) in body weight. Participants weighing less than 8.5 kg can be considered for enrollment after discussion with the sponsor
• Have been previously treated with at least 1 biologic therapy and, in the opinion of the investigator, did not respond or are no longer responding to therapy. If the participant has been diagnosed with CANDLE, Nakajo-Nishimura Syndrome (NNS), SAVI, AGS, or an equivalent syndrome, the need for previous biologic therapy is not required. Not required for patients with AGS.
• Require treatment with oral corticosteroids (≥0.15 milligrams per kilogram per day [mg/kg/d] of prednisone or its equivalent) for control of systemic signs and symptoms of their chronic inflammatory disease for at least 2 weeks prior to study entry, or in the opinion of the investigator, have failed an adequate course of steroids
• Have had previous documented elevations in acute-phase reactants (for example, high sensitivity C-reactive protein) considered to be the result of the inflammatory disease (patients with CANDLE or CANDLE-related conditions only)
• Have the ability to provide informed consent or have legal representative who is willing and able to provide written informed consent, provided that assent is obtained from participants at an age-appropriate level
|
|
E.4 | Principal exclusion criteria |
• Have received an immunosuppressive biologic agent/monoclonal antibody within 4 half-lives prior to entry, for example, anakinra (4 half-lives=18 hours); etanercept (4 half-lives=18 days); infliximab; adalimumab (4 half-lives=36 days); use of intravenous immune globulin (IVIg) is permitted
• Are pregnant or nursing at the time of entry
• Are females of childbearing potential (women >12 or who have had at least 1 menstrual period regardless of age) who are sexually active and who do not agree to use 2 forms of highly effective birth control during the study and for at least 28 days following the last dose of investigational product
• Are males who do not agree to use 2 forms of highly effective birth control while engaging in sexual intercourse with female partners of childbearing potential during the study and for at least 28 days following the last dose of investigational product
• Have had symptomatic herpes zoster infection within 12 weeks prior to entry or during the screening period
• Have a history of disseminated/complicated herpes zoster (for example, multidermatomal involvement, ophthalmic zoster, central nervous system [CNS] involvement, postherpetic neuralgia)
• Have evidence of active infection, at the time of entry or during the screening period, that in the opinion of the investigator, would pose an unacceptable risk for participating in the study
• Have a history of active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV)
• Have documented high titer autoantibodies suggestive clinically of autoimmune diseases other than severe JDM
• Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
• Have had a serious systemic or local infection (including an infectious mononucleosis-like illness or herpes zoster) within 12 weeks prior to entry or during the screening period
• Have been exposed to a live vaccine within 12 weeks prior to entry or are expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study.
• Have had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB
• Have a serious and/or unstable illness that, in the opinion of the investigator, poses an unacceptable risk for the participant's participation in the study
• Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of <40 milliliters/minute/1.73 per square meter
• Have or have had a history of lymphoproliferative disease; or signs or symptoms suggestive of possible lymphoproliferative disease, or active primary or recurrent malignant disease; or been in remission from clinically significant malignancy for <5 years Note: Participants with resolved cervical dysplasia, or no more than 3 successfully treated basal-cell carcinoma of the skin, may participate in this study
• Have a history of chronic alcohol abuse or intravenous (IV) drug abuse within the 2 years prior to entry
• Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures
Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
CANDLE diary: reduction in mean daily score to <0.5
SAVI diary: reduction in mean daily score, exclusive of respiratory/breathing symptoms, to <1.0 and respiratory/breathing symptoms score a <1.0 increase from baseline
JDM diary: reduction in mean score by 1 point in at least 3 categories.
AGS diary: reduction in mean daily score to <0.5. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
End of study (date of regulatory approval of this compound for any indication in any country) |
|
E.5.2 | Secondary end point(s) |
CANDLE, CANDLE-related, SAVI patients receiving steroids: decrease in the daily dose of corticosteroids (systemic corticosteroids <0.15 mg/kg/day oral prednisone or a decrease of at least 50% of the patient’s daily dose at baseline)
JDM patients receiving steroids: decrease in the daily dose of corticosteroids (systemic corticosteroids <0.2 mg/kg/day oral prednisone or a decrease of at least 25% of the patient’s daily dose at baseline)
AGS: N/A |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
End of study (date of regulatory approval of this compound for any indication in any country) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |